Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Bacillus Subtilis COVID-19 Vaccine Pilot Study
NCT05239923Phase 1Completed
- Sponsor
- DreamTec
- Start
- Aug 2021
- Primary completion
- Nov 2021
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 1, open-label trial of Bacillus subtilis spores expressing SARS-CoV-2 Spike RBD in coronavirus disease 2019 (COVID-19), sponsored by DreamTec. Primary endpoints: Safety of the engineered Bacillus subtilis at 3 months and Concentration of Neutralizing IgG antibody against Receptor binding domain of spike protein of SARS-CoV2 at 2 months. Started Aug 2021; status: completed.
02
Drugs
Bacillus subtilis spores expressing SARS-CoV-2 Spike RBD
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05239923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05239923.